Please assess the completion status of the following clinical trial:

Trial Title: Switch to Unboosted Atazanavir With Tenofovir Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV infected adults at least 19 years of age~2. Willing and able to provide informed consent to study participation~3. Currently receiving a regimen including atazanavir 300mg/ritonavir 100mg daily with either tenofovir/emtricitabine (FTC) or tenofovir/lamivudine (3TC), for at least 3 months~4. Plasma viral load (VL) \<40 copies/mL for at least 2 consecutive measurements including the screening value, and \< 150 copies/mL continuously for at least 3 months prior to screening~5. Current regimen is first antiretroviral regimen, or if not first regimen, no evidence of resistance to any nucleosides (NRTIs) or protease inhibitors (PIs) on previous resistance tests~6. Any CD4~Exclusion Criteria:~1. Clinically significant intolerance or toxicity with current regimen precluding regimen continuation (e.g. intolerance/toxicity to ritonavir necessitating ritonavir discontinuation)~2. pregnancy or breast-feeding~3. antiretroviral regimen including any nonnucleoside reverse transcriptase inhibitor (nevirapine, efavirenz, or etravirine)~4. antiretroviral regimen including any protease inhibitor other than atazanavir and ritonavir~5. concomitant treatment with proton pump inhibitors, rifampin, St. John's wort, or garlic supplements. (Antacids and H2 receptor antagonists will be allowed provided their dosing is separated from atazanavir administration by at least 2 and 10 hours, respectively).

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Switch (Type: EXPERIMENTAL): switch to unboosted atazanavir 400mg daily with the same nucleoside (NRTI) backbone
- Continuation (Type: ACTIVE_COMPARATOR): continue on current regimen of atazanavir/ritonavir 300mg/100mg with the same nucleoside (NRTI) backbone

Based on this trial design, predict the completion outcome and termination type (if applicable).